This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Brightness alteration: Difference between revisions
Jump to navigation
Jump to search
>Josikins revisiting effect overhauls and proofreading/adding minor tweaks |
>Graham References |
||
| Line 1: | Line 1: | ||
'''Brightness alteration''' can be described as a distortion or change in the levels of perceived brightness comprising a person's vision. This usually results in the person's vision becoming darker and gloomier, but could also potentially result in it becoming lighter and brighter depending on the person's environment and substances they have consumed. | '''Brightness alteration''' can be described as a distortion or change in the levels of perceived brightness comprising a person's vision.<ref>Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562. https://dx.doi.org/10.1093/schbul/3.4.560</ref> This usually results in the person's vision becoming darker<ref name="psilocybin">Fischer, R., Hill, R. M., & Warshay, D. (1969). Effects of the psychodysleptic drug psilocybin on visual perception. Changes in brightness preference. Experientia, 25(2), 166-169. https://doi.org/10.1007/BF01899102</ref><ref>Abraham, H. D., & Wolf, E. (1988). Visual function in past users of LSD: Psychophysical findings. Journal of Abnormal Psychology, 97(4), 443. http://dx.doi.org/10.1037/0021-843X.97.4.443</ref> and gloomier, but could also potentially result in it becoming lighter and brighter<ref name="psilocybin"/><ref>Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> depending on the person's environment and substances they have consumed. | ||
Brightness alteration is most commonly induced under the influence of [[dosage#common|moderate]] [[dosage|dosages]] of [[hallucinogen|hallucinogenic]] compounds, such as [[psychedelic|psychedelics]], [[dissociative|dissociatives]], and [[cannabinoid|cannabinoids]]. | Brightness alteration is most commonly induced under the influence of [[dosage#common|moderate]] [[dosage|dosages]] of [[hallucinogen|hallucinogenic]] compounds, such as [[psychedelic|psychedelics]], [[dissociative|dissociatives]], and [[cannabinoid|cannabinoids]]. | ||
| Line 19: | Line 19: | ||
|Belongs to=Visual effects | |Belongs to=Visual effects | ||
}} | }} | ||
===References=== | |||
<references/> | |||
Revision as of 23:51, 22 February 2018
Brightness alteration can be described as a distortion or change in the levels of perceived brightness comprising a person's vision.[1] This usually results in the person's vision becoming darker[2][3] and gloomier, but could also potentially result in it becoming lighter and brighter[2][4][5] depending on the person's environment and substances they have consumed.
Brightness alteration is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and cannabinoids.
Psychoactive substances
Compounds within our psychoactive substance index which may cause this effect include:
- 2-FEA
- 2-FMA
- 25B-NBOH
- 25C-NBOH
- 25I-NBOH
- 25I-NBOMe
- 3-FPM
- 3C-E
- 3C-P
- 4-AcO-DET
- 4-AcO-MiPT
- 4-HO-DPT
- 4-HO-DiPT
- 4-HO-EPT
- 4-HO-MPT
- 4-HO-MiPT
- 5-MeO-DiPT
- A-PHP
- A-PVP
- Allylescaline
- Amphetamine
- Blue Lotus
- Cannabis
- Cyclazodone
- DET
- DOB
- DOC
- DOI
- DOM
- Datura
- Desoxypipradrol
- Diphenhydramine
- LSM-775
- Lisdexamfetamine
- MET
- MPT
- Memantine
- Methallylescaline
- MiPT
- PARGY-LAD
- PRO-LAD
- Propylhexedrine
- Proscaline
- Βk-2C-B
See also
- Responsible use
- Hallucinogens
- Deliriants
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
External links
References
- ↑ Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562. https://dx.doi.org/10.1093/schbul/3.4.560
- ↑ 2.0 2.1 Fischer, R., Hill, R. M., & Warshay, D. (1969). Effects of the psychodysleptic drug psilocybin on visual perception. Changes in brightness preference. Experientia, 25(2), 166-169. https://doi.org/10.1007/BF01899102
- ↑ Abraham, H. D., & Wolf, E. (1988). Visual function in past users of LSD: Psychophysical findings. Journal of Abnormal Psychology, 97(4), 443. http://dx.doi.org/10.1037/0021-843X.97.4.443
- ↑ Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753
- ↑ Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006